Even more impressive, 42% of tirzepatide users lost 15% or more of their body weight, compared to just 18% of semaglutide users
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes Frontiers in Public Health
Yet despite its importance, achieving meaningful systemic levels through oral delivery has always been difficult
Many highlight how easy the new macro and nutrient tracking features make it to stay on target, while coaches and community groups keep them motivated and accountable along the way
I explore all this in a feature story published today, which marks the kick off of a new series from The Globe and Mail called Skinny Inc, about the big business of weight-loss drugs: Also published today is a companion piece from my colleague Kelly Grant who digs deeper into the research and patient experience of these drugs: We have more coming in the series over the coming weeks, including stories on influencers, insurance coverage, the effect on the food industry and more
These dosing ranges come from research settings and are not recommendations for personal use